当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Laura Soysal
Recent data from sizable cohort studies shows that persons with type 2 diabetes have a greater cancer incidence. The probable causes of this relationship are yet unknown, though, as of this writing. These glucosehungry cells may get extra glucose from hyperglycemia, the most significant aspect of diabetes, which also leads to oncogenesis, apoptosis resistance, and chemotherapy-resistant tumour cells [1]. The impact of hyperglycemia on the advancement of cancer in cancer patients with abnormal blood glucose levels should not be disregarded given the link between diabetes and malignancies [2]. In this article, we discuss the role that hyperglycemia plays in the development of cancer and its management, as well as how it might influence the phenotypic of cancer cells and promote drug resistance. Consequently, managing hyperglycemia may Hyperglycemia, also known as high blood glucose, is a condition that occurs when there is either an insufficient quantity of insulin in the body or when the body is unable to properly utilise the insulin that is present [3].